Orthocell Limited
Orthocell Limited
Your view on OCC.AX
Overview
What the company does, where it operates, and who runs it.
About Orthocell Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul Frederick Anderson
- Headquarters
- Building 191, Murdoch, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul Frederick Anderson
- Headquarters
- Building 191, Murdoch, WA, AU
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Orthocell Limited, and the rating behind it. OCC.AX last traded at AUD 0.73; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Orthocell Limited. Starting points for Orthocell Limited: EPS -AUD 0.05, beta -0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Orthocell Limited. Orthocell Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Orthocell Limited. Trailing twelve-month EPS for Orthocell Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Orthocell Limited. Orthocell Limited has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Orthocell Limited valued side by side against its closest peers. Orthocell Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Orthocell Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Orthocell Limited executives and directors. Shares of Orthocell Limited have traded between AUD 0.70 and AUD 1.60 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Orthocell Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Orthocell Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Orthocell Limited. Coverage tracks Orthocell Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.